Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Trading in Regeneron Common Stock Halted

June 17, 2011 By Bio-Medicine.Org

TARRYTOWN, N.Y., June 17, 2011 /PRNewswire/ — Regeneron
Pharmaceuticals, Inc. (Nasdaq:
REGN
) announced that NASDAQ has halted trading of the company’s
common stock today.  The Dermatologic and Ophthalmic Drugs
Advisory Committee of the U.S. Food and Drug Administration (FDA)
is meeting today to discuss the company’s Biologics License
Application (BLA) for EYLEA™, also known as VEGF Trap-Eye,
for the treatment of the neovascular form of age-related macular
degeneration (wet AMD).  

Regeneron submitted a BLA for marketing approval in wet AMD in
the U.S. in February 2011 and received a Priority Review
designation.  Under Priority Review, the target date for an
FDA decision on the EYLEA BLA is August 20, 2011.

About EYLEAVascular Endothelial Growth Factor (VEGF) is a
naturally occurring protein in the body.  Its normal role in a
healthy organism is to trigger formation of new blood vessels
(angiogenesis) supporting the growth of the body’s tissues and
organs.  However, in certain diseases, such as age-related
macular degeneration, it is also associated with the growth of
abnormal new blood vessels in the eye, which exhibit vascular
permeability and lead to edema.  

EYLEA (aflibercept ophthalmic solution), also known as VEGF
Trap-Eye, is a fully human fusion protein, consisting of portions
of VEGF receptors 1 and 2, that binds all forms of VEGF-A along
with the related Placental Growth Factor (PlGF).  EYLEA is a
specific and highly potent blocker of these growth factors.
 EYLEA is specially purified and contains iso-osmotic buffer
concentrations, allowing for injection into the eye.

Regeneron and Bayer HealthCare are collaborating on the
global development of EYLEA for the treatment of the neovascular
form of age-related macular degeneration (wet AMD), central retinal
vein occlusion (CRVO), diabetic macu

‘/>”/>

SOURCE

Related Articles Read More >

Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions
Koya Medical’s Dayspring device
Koya Medical reports positive early results in Dayspring lymphedema trial

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech